INDUSTRY SPONSORED SYMPOSIA

Lunch Symposia
Monday, June 9  12.00 - 13.30
Tuesday, June 10  12.00 - 13.30
Wednesday, June 11  12.00 - 13.30

Evening Symposia
Tuesday, June 10  19.00
Current and future challenges in anaemia management

Chair: A. Levin, Vancouver, Canada
E. Ritz, Heidelberg, Germany

Introduction
E. Ritz, Heidelberg, Germany

Immunogenicity: does route of administration solve the problem?
H. Schellekens, Utrecht, The Netherlands

Optimising anaemia management through subcutaneous administration
A. Besarab, Detroit, USA

Managing a fateful alliance: anaemia and cardiovascular outcomes
K.-U. Eckardt, Berlin, Germany

Managing anaemia and diabetes: a future challenge for nephrologists
E. Ritz, Heidelberg, Germany

Panel discussion

Closing remarks
A. Levin, Vancouver, Canada

Organised by ROCHE

Chair: G. London, Fleury Merogis, France
A. Santoro, Bologna, Italy

Introduction
G. London, Fleury Merogis, France

New approach in blood pressure management
C.F.M. Franssen, Groningen, The Netherlands

Anticoagulation effects on lipid metabolism
J. Chanard, Reims, France

Arrhythmias in dialysis: genesis and control
A. Santoro, Bologna, Italy

Panel discussion

Organised by HOSPAL
Controversies in Mineral Metabolism and Bone Disease in CKD

Chair: T. Drüeke, Paris, France
S. Moe, Indianapolis, USA

Controversies in Bone Turnover
T. Drüeke, Paris, France

Controversies in Osteoporosis
J. Cunningham, London, United Kingdom

Controversies in Vascular Calcification
S. Moe, Indianapolis, USA

Organised by
NATIONAL KIDNEY FOUNDATION
MONDAY

521

INDUSTRY SPONSORED SYMPOSIA

Monday, June 9 12.00–13.30
ROOF GARDEN LOBBY

Safety of the available IV iron compounds

Chair: W. H. Hörl, Vienna, Austria

Complex stability of IV iron and release in serum
P. Langguth, Mainz, Germany

Results from a comparative in vitro toxicology study
of iron sucrose and the new low molecular weight
iron dextran
R. Carlini, Caracas, Venezuela

Is free iron toxic for the cardiovascular system?
J.J.M. Marx, Utrecht, The Netherlands

Surprising new information of the adverse drug
event rate of various IV iron compounds from
millions of doses administered
G. M. Chertow, San Francisco, USA

Effects of intravenous iron on cardiovascular and
all-cause mortality
P. Zager, Albuquerque, USA

Organised by NEBO
Tuesday, June 10 12.00–13.30
HALL 1

Setting standards in Dialysis: European Best Practice Guidelines

Chair: R. Vanholder, Ghent, Belgium
C. Tetta, Bad Homburg, Germany

Why European Best Practice Guidelines?
R. Vanholder, Ghent, Belgium

Dialysis fluid purity
B. Canaud, Montpellier, France

Importance of biocompatibility in hemodialysis
R. Vanholder, Ghent, Belgium

Hemodialysis adequacy – Targets and ways to achieve them
L. Pedrini, Seriate, Italy

European Best Practice Guidelines in the provider’s practice
D. Marcelli, Bad Homburg, Germany

Organised by FRESENIUS MEDICAL CARE
Tuesday, June 10 12.00–13.30
HALL 2

Living donor kidney transplantation: challenging concepts

Chair: R.S. Gaston, Birmingham, USA
J. Wadstrom, Uppsala, Sweden

Introduction
R.S. Gaston, Birmingham, USA

Pre-emptive transplantation for positive outcomes
H-U. Meier-Kriesche, Gainesville, USA

Early transplantation or continued dialysis: an economic and legal assessment
H. Kliemt, Duisberg, Germany

Donor outcomes: an evidence-based evaluation
G.T. Thiel, Bottmingen, Switzerland

Surgical advances in living donor nephrectomy
J. Wadström, Uppsala, Sweden

Pioneering approaches to expand the living donor pool
R.S. Gaston, Birmingham, USA

Questions and close
J. Wadström, Uppsala, Sweden

Organised by FUJISAWA
Preventing and managing acute renal failure in cancer patients

Chair: N. Lameire, Ghent, Belgium

Is acute renal failure different in cancer patients? Causes, pathology and particularities.
C. Flombaum, New York, USA

When can we avoid dialysis? Strategies for preventing acute renal failure.
D. Moreau, Paris, France

Risk and prevention of acute renal failure in cancer. Where are we going?
C. Ronco, Vicenza, Italy

Organised by SANOFI-SYNTHELABO
Tuesday, June 10 12.00–13.30
HALL 4/5

Opening doors to better anaemia management in haemodialysis patients

Chair: J.F.E. Mann, Munich, Germany

Welcome and introduction
J.F.E. Mann, Munich, Germany

Are there barriers to treating haemodialysis patients with IV epoetin?
J.A. Rossert, Paris, France

Setting target Hb levels: a recipe for underachievement?
E.J. Will, Leeds, United Kingdom

Strategies for achieving outcomes in anaemia management
D. Richardson, York, United Kingdom

Do we have enough data to optimally manage anaemia in diabetic haemodialysis patients?
A. Levin, Vancouver, Canada

Panel discussion and closing remarks

Organised by ORTHO BIOTECH
Fabry Nephropathy - A treatable disease?

Chair: P. Jaeger, Nice, France

Underlying pathology and natural course
F. Barbey, Lausanne, Switzerland

Fabry disease - Multi organ manifestations
F. Dehout, Charleroi, Belgium

Outcome of Enzyme Replacement Therapy (ERT)
A. Schwarting, Mainz, Germany

Discussion

Organised by TKT
Evidence-based medicine in dialysis therapy: between clinical practice, ethics and economics

Chair: F.K. Port, Ann Arbor, USA

Outline and goals
F.K. Port, Ann Arbor, USA

Definition: what is evidence-based medicine?
R.A. Wolfe, Ann Arbor, USA

Examples of various evidence levels in ESRD therapy
F. Locatelli, Lecco, Italy

Economical and ethical issues and in developing countries
R. Barsoum, Cairo, Egypt

General ethical considerations
U. Wiesing, Tübingen, Germany

Panel discussion

Organised by MEMBRANA
Improving management of ESRD patients: focus on anaemia and secondary hyperparathyroidism

Chair: K.-U. Eckardt, Berlin, Germany
W.H. Hörl, Vienna, Austria

Introduction
Non-classical cardiovascular risk factors in ESRD patients: role of anaemia and SHPT
E. Ritz, Heidelberg, Germany

Taking anaemia treatment one step further
M. Wilkie, Sheffield, United Kingdom

Clinical update on cinacalcet: a novel calcimimetic agent
T. Drüeke, Paris, France

Discussion and close

Organised by AMGEN
Renal involvement in metabolic disorders

Chair: J.H.H. Ehrich, Hannover, Germany
      J.-P. Grünfeld, Paris, France

Glomerular and tubular dysfunction in inborn errors of metabolism
J. Rodriguez-Soriano, Bilbao, Spain

Long-term complications of cystinosis
B. Enke, Hannover, Germany
J.H.H. Ehrich, Hannover, Germany
M. Broyer, Lyon, France

Forever growing with cystinosis
J. Terry, London, United Kingdom

Metabolic disorders with late renal involvement: an integrated approach
J.-P. Grünfeld, Paris, France

Discussion and conclusion
J.H.H. Ehrich, Hannover, Germany
J.-P. Grünfeld, Paris, France

Organised by ORPHAN EUROPE
Bone, heart and hyperphosphataemia: an evolving paradigm in ESRD management?

Chair: E. Ritz, Heidelberg, Germany
H. Malluche, Lexington, USA

Greeting and introduction
E. Ritz, Heidelberg, Germany
H. Malluche, Lexington, USA

Importance of hyperphosphataemia in the cardio-renal axis
W.G. Goodman, Los Angeles, USA

The importance of bone health in ESRD: out of the frying pan, into the fire?
H. Malluche, Lexington, USA

Improving phosphate binder therapy as a way forward
A. Hutchison, Manchester, United Kingdom

Improving outcomes in hyperphosphataemia
M.E. De Broe, Antwerp, Belgium

Panel discussion and closing remarks

Organised by SHIRE
Wednesday, June 11 12.00–13.30
HALL 1

N.E.P.P. - New Evidence in PD Prescriptions

Chair: J. Plum, Düsseldorf, Germany

Nutritional impact: increased muscle uptake of amino acids in patients treated with amino acid solution as measured by Positron Emission Tomography
M. Asola, Turku, Finland

Exploring new evidence: clinical benefits of icodextrin solution
S.J. Davies, Stoke-on-Trent, United Kingdom

PD solutions’ impact on glycaemic control in diabetic CAPD patients as assessed by Continuous Glucose Monitoring System (CGMS)
C. McIntyre, London, United Kingdom

Prescribing advanced solutions in combination: positive impact on clinical outcomes
P. ter Wee, Amsterdam, The Netherlands

Organised by BAXTER
Prevention and remission of vascular disorders in renal diseases

Chair: T. Drüeke, Paris, France

Vascular pathology in renal disease
C. Wanner, Würzburg, Germany

Fabry disease and the impact of enzyme replacement therapy
B. Brenner, Boston, USA

Modifications of cardiovascular risk factors in CKD
U. Querfeld, Berlin, Germany

Organised by GENZYME
Renal Transplantation and Immunology. Unique challenges and innovative solutions

Chair: U. Frei, Berlin, Germany

Refining the management of nephrotic syndrome. Understanding the choices
C. Ponticelli, Milan, Italy

Expanding the evidence base. Effective use of registry data
M. Schnitzler, Saint Louis, USA

Minimizing risk of calcineurin toxicity. A new precision
P. Keown, Vancouver, Canada

Discussion

Organised by NOVARTIS
INDUSTRY SPONSORED SYMPOSIA

Wednesday, June 11
Hall 4/5

12.00–13.30

Our focus in dialysis and apheresis - quality and innovation

Chair: H.-W. Schneider, Stuttgart, Germany

Welcome and Introduction
H.-W. Schneider, Stuttgart, Germany

Optimal treatment strategy in ARF and MODS
C. Ronco, Vicenza, Italy

How to assess dialysis dose? Kt/V for urea plus Kt/V for $\beta_2$-Microglobulin?
H. Mann, Aachen, Germany

Adsorption of endotoxins by apheresis - A new approach in the treatment of septic patients
S. Bengsch, Munich, Germany

Heparin-induced extracorporeal LDL-precipitation in sudden hearing loss - An approved method for a new indication
M. Suckfuell, Munich, Germany

Conclusion
H.-W. Schneider, Stuttgart, Germany

Organised by B. BRAUN
Wednesday, June 11  
12.00–13.30

Hall 9

New concepts of the biocompatibility of the dialysis membranes

Chair: W.H. Hörl, Vienna, Austria

Biocompatibility of dialysis membranes - still of clinical relevance?
W.H. Hörl, Vienna, Austria

Biocompatibility of dialysis membranes: from complement activation to apoptosis in neutrophils
A.R. Rosenkranz, Innsbruck, Austria

PMMA-based membranes and protein leakage: effects on inflammatory cytokines and short-term clinical outcome
F. Galli, Perugia, Italy

Organised by TORAY
Calcification or ‘Phosification’: considerations of calcium phosphate deposition

Chair: J. Silver, Jerusalem, Israel

Phosphate control and calcification from a cardiologist’s perspective
P.A. McCullough, Royal Oak, USA

Treatment of hyperphosphatemia: controversies and recommendations
W. Qunibi, San Antonio, USA

Acid loading from Sevelamer HCl; mechanism and implications
C. Nolan, San Antonio, USA

Organised by BRAINTREE
Dialysis Opinion Symposium
10-year Anniversary, featuring:
I. Preservation of Renal Function
II. Opinions on Dialysis Dose and Fluid Quality

Chair: E. Ritz, Heidelberg, Germany

Preservation of renal function in predialysis patients
N. Lameire, Ghent, Belgium

Preservation of renal function in haemodialysis patients
W.H. Hörl, Vienna, Austria

Preservation of renal function in peritoneal dialysis patients
O. Heimbürger, Stockholm, Sweden

Result from a survey among dialysis professionals during 2002 on preservation of renal function
I. Ledebo, Lund, Sweden

A decade of opinions on dialysis dose and adequacy
C. Ronco, Vicenza, Italy

A decade of opinions on dialysis fluid quality
G. Lonnemann, Langenhagen, Germany

Organised by GAMBRO
15 Years Growth Hormone Treatment in CRF: Conclusions and Perspectives

Chair: O. Mehls, Heidelberg, Germany
M. Broyer, Paris, France

Effect of GH treatment on final height
D. Haffner, Berlin, Germany

GH treatment in patients with renal allografts: a two-year randomized study in 180 patients
M. Broyer, Paris, France

Is the risk of organ transplant rejection really increased by GH treatment?
R.N. Fine, Stony Brook, USA

Principles of optimising and individualizing GH therapy
M. Ranke, Tübingen, Germany

Organised by PHARMACIA
Wednesday, June 11 12.00–13.30
HALL 15.2

Management of hypertension and cardio-renal disease in diabetic and other high-risk patients

Chair: H.-H. Parving, Aarhus, Denmark

Welcome address
H.-H. Parving, Aarhus, Denmark

Cardiovascular risk in the renal/diabetes patient with hypertension
H.-H. Parving, Aarhus, Denmark

Effectively achieving goals – the need for a multiple drug regimen in the renal/diabetes patient
M. Epstein, Miami, USA

New evidence on the importance of blood pressure control – ALLHAT and other recent trials
K. Jamerson, Ann Arbor, USA

New hypertension guidelines and how to implement them in daily practice – what do we still not know?
L. Hunsicker, Iowa City, USA

Concluding remarks
H.-H. Parving, Aarhus, Denmark

Organised by PFIZER NY
INDUSTRY SPONSORED SYMPOSIA

Tuesday, June 10 19.30–20.30
HALL 2

Long-term patient management: what’s the evidence?

Chair: U. Frei, Berlin, Germany

Introductory remarks
U. Frei, Berlin, Germany

Minimising immunosuppressive risk factors
Y. Vanrenterghem, Leuven, Belgium

PTDM: risk assessment and management strategies
J. Van Hooff, Maastricht, the Netherlands

Renal function: defining long-term success
J. Pascual, Madrid, Spain

Evaluating switch therapy options
U. Kunzendorf, Kiel, Germany

Panel discussion

Concluding remarks
U. Frei, Berlin, Germany

Organised by FUJISAWA
Who wants to defeat anaemia? – An interactive insight into anaemia management today.

Chair: F. Locatelli, Lecco, Italy  
N. Muirhead, London, Canada

Introduction  
N. Muirhead, London, Canada

Once-weekly treatment with epoetin beta  
F. Locatelli, Lecco, Italy

Dose tailoring strategies in haemodialysis patients: a discussion of case studies  
W. Kleophas, Düsseldorff, Germany

Dose tailoring strategies in haemodialysis patients: an interactive quiz  
All

Individualising anaemia treatment: a discussion of case studies  
N. Muirhead, London, Canada

Individualising anaemia treatment: an interactive quiz  
All

Closing remarks  
N. Muirhead, London, Canada

Organised by ROCHE
INDUSTRY SPONSORED SYMPOSIA

Tuesday, June 10 19.00–21.00
HALL 7

Treating the cardiovascular burden: helping the diabetic patient

Chair: B. Williams, Leicester, United Kingdom
H.-H. Parving, Aarhus, Denmark

Opening remarks
B. Williams, Leicester, United Kingdom

Understanding the importance of cardiovascular disease and diabetes
M. Cooper, Heidelberg, Australia

New insights into managing the diabetic patient with renal disease
H.-H. Parving, Aarhus, Denmark

New insights into managing the diabetic patient with hypertension
L. Lindholm, Umea, Sweden

Where do we go from here – Nephrologists’ view of treating the diabetic patient
B. Williams, Leicester, United Kingdom

Closing remarks
H.-H. Parving, Aarhus, Denmark

Organised by MERCK SHARP & DOHME
Renal function: the new target for improved outcomes in renal transplantation

Chair: J. Floege, Aachen, Germany

Introduction
J. Floege, Aachen, Germany

The relationship between renal function and graft survival
S. Hariharan, Milwaukee, USA

Long-term data from Sirolimus studies in de novo kidney transplantation
H. Kreis, Paris, France

Improving kidney function by converting patients from CNI- to Sirolimus-based therapy
H.-H. Neumayer, Berlin, Germany

Sirolimus: rationale for use in patients with post-transplant malignancy?
E. Geissler, Regensburg, Germany

Discussion

Organised by WYETH
Large Clinical Trials

Chair: K.-W. Kühn, Karlsruhe, Germany
C. Wanner, Würzburg, Germany

Opening remarks
K.-W. Kühn, Karlsruhe, Germany

HPS: The MRC/BHF Heart Protection Study. The influence of the Heart Protection Study on ongoing and planned clinical studies
R. Collins, Oxford, United Kingdom

Beyond 4D: Further issues in renal patients
C. Wanner, Würzburg, Germany

SHARP: A Study of Heart and Renal Protection
C. Baigent, Oxford, United Kingdom

Closing remarks
C. Wanner, Würzburg, Germany

Organised by PFIZER GERMANY
Tuesday, June 10 19.00–21.00
HALL 15.2

Dialysis Quality above and beyond the HEMO Study and the European Best Practice Guidelines

Chair: F.C. Luft, Berlin, Germany

Implications of the HEMO study for future chronic therapy
A.K. Cheung, Salt Lake City, USA

European Best Practice Guidelines for HD – A key for the future to improve quality
R. Vanholder, Ghent, Belgium

Convective therapies – Enhanced removal of large solutes…and more?
R.A. Ward, Louisville, USA

Organised by GAMBRO
Tuesday, June 10 19.00–20.30
Hotel Adlon, Berlin, Pariser Platz

The future role of the nephrologist: from dialysis to molecular medicine

Chair: I. Macdougall, London, United Kingdom
J. Cunningham, London, United Kingdom

Enhancement of anaemia therapy through glycoengineering
S. Elliot, Thousand Oaks, USA

New insights in bone biology and bone disease – role of hormones, growth factors and cytokines
S. Moe, Indianapolis, USA

Role of cytokines in the malnutrition, inflammation, atherosclerosis and anaemia syndrome of chronic kidney disease
P. Stenvinkel, Stockholm, Sweden

The future today: stem cells and vascular repair in nephrology
H. Haller, Hannover, Germany

Discussion and close

Organised by AMGEN
INDUSTRY SPONSORED SYMPOSIA

Tuesday, June 10 19.30–21.30  
Grand Ballroom I & II  
Grand Hyatt Berlin, Marlene-Dietrich-Platz 2

Renoprotection: earlier is better

Chair: R. Schmieder, Erlangen, Germany

Kidney damage in Type II Diabetes: is it preventable?  
L. Ruilope, Madrid, Spain

Benefits of intervention with AIIRAs in diabetic nephropathy with advanced proteinuria  
L. Hunsicker, Iowa City, USA

Clinical implications of recent trials: the Nephrologist’s role  
M. Weir, Baltimore, USA

Panel Discussion and Questions and Answers  
All

Organised by  
BRISTOL MYERS SQUIBB/SANOFI SYNTHELABO